Advertisement

Topics

Th1/17 hybrid T cells offer potent and durable anti-tumour response in preclinical model

13:06 EST 9 Nov 2017 | ecancermedicalscience

In recent years, the search for new cancer treatments has increasingly focused on immunotherapies that harness the body's own defenses to fight tumours. Adoptive cell therapy (ACT) is a powerful immunotherapeutic strategy that can effectively control...

Original Article: Th1/17 hybrid T cells offer potent and durable anti-tumour response in preclinical model

NEXT ARTICLE

More From BioPortfolio on "Th1/17 hybrid T cells offer potent and durable anti-tumour response in preclinical model"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...